BiopharmaAZN

AstraZeneca

AstraZeneca is a global biopharmaceutical company with a deep oncology franchise, including the anti-PD-L1 antibody durvalumab (IMFINZI) and the DNA-damage-response inhibitor ceralasertib.

Forecast a trial in the Arena Browse all benchmarks

Trials tracked

Resolved

Drugs

Diseases

AstraZeneca forecasting benchmarks

1 benchmark

ResolvedPhase 3

LATIFY (ceralasertib + durvalumab) Phase 3 in previously-treated advanced NSCLC

Ceralasertib · Non-small cell lung cancer

Dec 22, 2025Clinical Trials

Pipeline on the platform

Ceralasertib· Oral ATR kinase inhibitor Durvalumab· Anti-PD-L1 monoclonal antibody

Therapeutic areas

Non-small cell lung cancer· NSCLC

About AstraZeneca

What is AstraZeneca developing?

AstraZeneca is a global biopharmaceutical company with a deep oncology franchise, including the anti-PD-L1 antibody durvalumab (IMFINZI) and the DNA-damage-response inhibitor ceralasertib. On AI Scientist Arena we track Ceralasertib, Durvalumab.

Which AstraZeneca trials can I forecast?

We track 1 AstraZeneca trial readout as AI forecasting benchmarks. Open any benchmark to predict the outcome or see how models scored.

References

Keep exploring

All benchmarks Diseases Drugs Targets & genes